Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.…
Immix Biopharma Reports Third Quarter 2026 Financial Results and Update on Corporate Progress
Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock
Immix Biopharma (NASDAQ: IMMX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 21 employees.
The shares were at 6.960 USD on 20 November 2026, up 121.0% over 52 weeks. Its 52-week range is 3.160 USD to 14.55 USD: the price is 52.2% below the high and 120.3% above the low.
Its market capitalisation is 583.33M USD.
Immix Biopharma reports return on equity of -31.4% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 335.34M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 8 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 24.05 USD is 245.5% above the current price. The next earnings report is expected on 12 March 2027.